Telix Pharmaceuticals is trading at A$14.52, down 7.87%, after quarterly revenue slipped 1% from Q2 despite rising 19% year over year. - The October 21 quarterly update reported revenue of US$245 million. - Telix reaffirmed FY2026 revenue and other income above US$1 billion and narrowed its R&D spending outlook. - A market report also cited profit-taking and expectations as possible factors; turnover was A$63.6 million.